Risk of second non-hematological malignancies among 376,825 breast cancer survivors

被引:84
作者
Brown, Linda Morris
Chen, Bingshu E.
Pfeiffer, Ruth M.
Schairer, Catherine
Hall, Per
Storm, Hans
Pukkala, Eero
Langmark, Froydis
Kaijser, Magnus
Andersson, Michael
Joensuu, Heikki
Fossa, Sophie D.
Travis, Lois B.
机构
[1] NCI, Div Canc Epidemiol & Genet, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA
[2] Karolinska Inst, Stockholm, Sweden
[3] Danish Canc Soc, Copenhagen, Denmark
[4] Finnish Canc Registry, FIN-00170 Helsinki, Finland
[5] Canc Registry Norway, Oslo, Norway
[6] Univ Helsinki, Cent Hosp, Helsinki, Finland
[7] Univ Oslo, Rikshosp, Radiumhosp Med Ctr, N-0027 Oslo, Norway
关键词
absolute risks; breast cancer; cohort study; competing risks; risk; survivor; second cancer; second malignancies; treatment;
D O I
10.1007/s10549-007-9509-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Breast cancer survivors are at increased risk of treatment-related second cancers. This study is the first to examine risk 30 or more years after diagnosis and to present absolute risks of second cancer which accounts for competing mortality. We identified 23,158 second non-hematological malignancies excluding breast in a population-based cohort of 376,825 one-year survivors of breast cancer diagnosed from 1943 to 2002 and reported to four Scandinavian cancer registries. We calculated standardized incidence ratios (SIR) and utilized a competing-risk model to calculate absolute risk of developing second cancers. The overall SIR for second cancers was 1.15 (95% confidence interval [CI] = 1.14-1.17). The SIR for potentially radiotherapy-associated cancers 30 or more years after breast cancer diagnosis was 2.19 (95% CI = 1.87-2.55). However, the largest SIRs were observed for women aged < 40 years followed for 1-9 years. At 20 years after breast cancer diagnosis, the absolute risk of developing a second cancer ranged from 0.6 to 10.3%, depending on stage and age; the difference in the absolute risk compared to the background population was greatest for women aged < 40 years with localized disease, 2.3%. At 30 years post breast cancer diagnosis, this difference reached 3.2%. These risks were small compared to the corresponding risk of dying from breast cancer. Although the absolute risks were small, we found persistent risks of second non-hematological malignancies excluding breast 30 or more years after breast cancer diagnosis, particularly for women diagnosed at young ages with localized disease.
引用
收藏
页码:439 / 451
页数:13
相关论文
共 82 条
  • [1] Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0
  • [2] ADAMI HO, 1984, J NATL CANCER I, V73, P1049
  • [3] Radiation therapy for breast cancer and increased risk for esophageal carcinoma
    Ahsan, H
    Neugut, AI
    [J]. ANNALS OF INTERNAL MEDICINE, 1998, 128 (02) : 114 - 117
  • [4] [Anonymous], 2006, Cancer Facts and Figures
  • [5] Tamoxifen therapy for breast cancer and endometrial cancer risk
    Bernstein, L
    Deapen, D
    Cerhan, JR
    Schwartz, SM
    Liff, J
    McGann-Maloney, E
    Perlman, JA
    Ford, L
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (19) : 1654 - 1662
  • [6] CANCER IN THE CONTRALATERAL BREAST AFTER RADIOTHERAPY FOR BREAST-CANCER
    BOICE, JD
    HARVEY, EB
    BLETTNER, M
    STOVALL, M
    FLANNERY, JT
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (12) : 781 - 785
  • [7] Boice JD., 2006, Cancer Epidemiology and Prevention, V3rd ed, P259
  • [8] Breslow NE, 1987, STAT METHODS CANC RE, VII
  • [9] Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer
    Buyse, Marc
    Loi, Sherene
    van't Veer, Laura
    Viale, Giuseppe
    Delorenzi, Mauro
    Glas, Annuska M.
    d'Assignies, Mahasti Saghatchian
    Bergh, Jonas
    Lidereau, Rosette
    Ellis, Paul
    Harris, Adrian
    Bogaerts, Jan
    Therasse, Patrick
    Floore, Arno
    Amakrane, Mohamed
    Piette, Fanny
    Rutgers, Emiel
    Sotiriou, Christos
    Cardoso, Fatima
    Piccart, Martine J.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (17): : 1183 - 1192
  • [10] Centers for Disease Control and Prevention (CDC), 2004, MMWR Morb Mortal Wkly Rep, V53, P526